Drug development to antagonise various kind of tumours
ImmunOs Therapeutics AG
Incorporated
04.12.2014Headquarters
SchlierenSupport
ImmunOs Therapeutics AG is leading the next generation of immunotherapies by fast-tracking new discoveries to enhance combination therapies with novel human immunomodulatory proteins that have a role in both the innate and adaptive immune system for cancer treatment.
News
ImmunOs Therapeutics secures USD 11M to advance cancer therapy (venturelab.swiss)
Immunos Therapeutics raises USD11 million (startupticker.ch)
The most promising Swiss biotech startups and scale-ups of 2024, according to investors (TOP 100)
Clinical advancements at ImmunOs Therapeutics and Noema Pharma (startupticker.ch)
Early-stage pharmaceutical companies make strides in cancer- and immunotherapy (startupticker.ch)
Green light for ImmunOs Therapeutics first clinical trial (startupticker.ch)
International and seasoned board members for Switzerland (startupticker.ch)
ImmunOs Therapeutics raises $74 Million to fund clinical trials (startupticker.ch)
ImmunOs Therapeutics raises CHF 71 million in B round (venturelab.swiss)
Experienced top managers join start-ups (startupticker.ch)
Startups welcome executives aboard (startupticker.ch)
On a growth path: Switzerland’s most promising scale-ups in 2021 (TOP 100)
25 most promising scale-ups in Switzerland (venturelab.swiss)
ImmunOs Therapeutics AG raises CHF 15M in Series A Financing (startupticker.ch)
UZH Life Sciences Fund and Schroder Adveq invest in ImmunOs Therapeutics (startupticker.ch)